The trajectory of Sildenafil presents a challenging picture for investors. While the initial launch generated massive returns, the expiration of its exclusive rights opened the avenue to off-brand alternatives, https://sidneyimnu388820.theisblog.com/42235257/sildenafil-and-big-pharma-a-precarious-bet